Sleep disturbances in Parkinson's disease;Zaburzenia snu w chorobie Parkinsona

Neurologia i Neurochirurgia Polska

Volumn 39, Issue 5, 2005, Pages 380-388

  Boczarska Jedynak, Magdalena ^a   Opala, Grzegorz ^a  

^a Katedra i Klinika Neurologii Wieku Podesz ego SAM SP Centralny Szpital Kliniczny ul Medyków 14   (Poland)

Author keywords

Dopaminergic therapy; Parkinson's disease; Quality of life; Sleep disturbances

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; MONOAMINE OXIDASE INHIBITOR;

AGE; AUTONOMIC NEUROPATHY; BRADYKINESIA; COMORBIDITY; DEMENTIA; DEPRESSION; DOPAMINERGIC NERVE CELL; HUMAN; INSOMNIA; LIMB MOVEMENT; MUSCLE RIGIDITY; NERVE CELL DEGENERATION; NEUROTRANSMISSION; NIGHTMARE; PARKINSON DISEASE; QUALITY OF LIFE; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SOMNOLENCE; SYMPTOMATOLOGY; TREMOR;

ANTIPARKINSON AGENTS; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SLEEP DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP, REM;

EID: 28244474118     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Friedman A. Epidemiologia, etiopatogeneza, rozpoznawanie i leczenie choroby Parkinsona. W: Choroba Parkinsona. alfa-medica press, Bielsko-Biała 1999; 30.
2. Ferreira J.J., Galitzky M., Montastruc J.L. i wsp. Sleep attacks and Parkinson's disease treatment. Lancet 2000; 355: 1333-1334.
3. Rascol O., Ferreira J.J., Desboeuf K. i wsp. Sleep disruption, daytime somnolence, and "sleep attacks" in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Neurology 2001; 56 (supl. 3): A212-213.
4. Askenasy J.J. M. Sleep in Parkinson's disease. Acta Neurol Scand 1993; 87: 167-170.
5. Shapiro C.M., Dement W.C. Znaczenie i epidemiologia zaburzeń sun. W: Shapiro C.M. ABC... zaburzeń snu. Wyd. Astrum, Wroclaw 1998; s. 10.
6. Daley J.T., Turner R.S., Bliwise D.L. i wsp. Nocturnal sleep and daytime alertness in the MPTP-treated primate. Sleep 1999; 22: 218-219.
7. Charles R., Cantor M.D., Stem M.B. Dopamine agonists and sleep in Parkinson's disease. Neurology 2002; 58 (supl. 1): S71-S78.
8. Jurkowlaniec E. Podstawowe mechanizmy snu i czuwania: udział głównych układów neurotransmiterowych mózgu. Sen 2002; 1: 21-32.
9. Ferreira J.J., Rascol O. Drug-related sleep disturbances and Parkinson's disease: effects of dopaminergic antiparkinsonian drugs on sleep and wakefulness. Eur J Neurol 2000; 7 (supl. 4): 26-35.
10. Andreu N., Chale J.J., Senard J.M. i wsp. L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol 1999; 22: 15-23.
11. Henderson J.M., Lu Y., Wang S. i wsp. Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. J Neurol Neurosurg Psychiatry 2003; 74: 956-958.
12. Tan E.K., Lum S.Y., Fook-Chong S.M. i wsp. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology 2002; 58: 465-468.
13. Hobson D.E., Lang A.E., Martin W.R. i wsp. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287: 455-463.
14. Homan C.N., Wenzyl K., Suppan M. i wsp. Sleep attacks after acute administration of apomorfine. Mov Disord 2000; 15 (supl 3): 108.
15. Paus S., Brecht H.M., Koster J. i wsp. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18: 659-667.
16. Tandberg E., Larsen J.P., Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14: 922-927.
17. Ulivelli M., Rossi S., Lombardi C. i wsp. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology 2002; 58: 462-465.
18. Frucht S., Rogers J.D., Greene P.E., i wsp. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908-1910.
19. Hauser R.A., Gauger L., Anderso W.M. i wsp. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15: 658-663.
20. Stocchi F., Brusa L., Vacca M. i wsp. Sleep disturbances in Parkinson's disease. Eur J Neurol 2000; 7 (supl. 4): 21-25.
21. Schapira A.H. Sleep attacks (sleep episodes) with pergolide. Lancet 2000; 355: 1332-1333.
22. Tan E.K. Piribedil-induced sleep attacks in Parkinson's disease. Fundam Clin Pharmacol 2003; 17: 117-119.
23. Olanow C.W., Fahn S., Muenter M. i wsp. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Dis 1994; 9: 40-47.
24. Shannon K.M., Bennett J.P. Jr., Friedman J.H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997; 49: 724-728.
25. Stover N.P., Okun M.S., Watts R.L. i wsp. Sleep attacks and excessive daytime sleepiness in Parkinson disease: a survey of 200 consecutive patients. Neurology 2001; 56 (supl. 3): A213.
26. Ferreira J.J., Galitzky M., Thalamas C. i wsp. Ropinirole-induced sedation: a randomized placebo-controlled study in healthy volunteers. Neurology 2001; 56 (supl. 3): A214.
27. Adler C.H., Sethi K.D., Hauser R.A. i wsp. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49: 393-399.
28. Pirker W., Happe S. Sleep attacks in Parkinson's disease. Lancet 2000; 356: 597-598.
29. Arnulf I., Konofal E., Merino-Andreu M. i wsp. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019-1024.
30. Santens P. Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor. Fundam, Clin Pharmacol 2003, 17: 121-123.
31. Bares M., Kanovsky P., Rektor I. Excessive daytime sleepiness and 'sleep attacks' induced by entacapone. Fundam Clin Pharmacol 2003; 17: 113-116.
32. Comella C., Nardine T., Diederich N. i wsp. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998; 51: 526-529.
33. Eisensehr I., v Lindeiner H., Jager M. i wsp. REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson's disease: is there a need for polysomnography? J Neurol Sci 2001; 186: 7-11.
34. Olson E., Boeve B.F., Silber M.H. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000; 123: 331-339.
35. Miyamoto M., Miyamoto T., Takekawa H. i wsp. Parasomnia as an occasion for the diagnosis of Parkinson's disease. Psychiatry Clin Neurosci 2001; 55: 273-274.
36. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46: 388-393.
37. Jeffinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991; 14: 153-197.
38. Lai Y.Y., Siegel J.M. Pontomedullary glutamate receptors mediating locomotion and muscle tone suppression. J Neurosci 1991; 11: 2931-2937.
39. Eisensehr I., Linke R., Noachtar S. i wsp. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000; 123: 1155-1160.
40. Arnulf I., Bonnet A.M., Damier P. i wsp. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55: 281-288.
41. Pappert E.J., Goetz C.G., Niederman F.G. i wsp. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 1999; 14: 117-121.
42. Wichniak A., Wierzbicka A., Jernajczyk W. Zespół niespokojnych nóg i periodyczne ruchy kończyn podczas snu - patogeneza i strategie leczenia. Neurol Neurochir Pol 2003; 37: 633-643.
43. Ruottinen H.M., Partinen M., Hublin C. i wsp. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54: 502-504.
44. Tan E.K., Lum S.Y., Wong M.C. Restless legs syndrome in Parkinson's disease. J Neurol Sci 2002; 196: 33-36.
45. Ondo W., Jankovic J. Restless legs syndrome: clinical-etiologic correlates. Neurology 1996; 47: 1435-1441.
46. Wetter T.C., Collado-Seidel V., Pollmacher T. i wsp. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 2000; 23: 361-367.
47. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982; 39: 739.
48. Chaudhuri K.R., Pal S., Bridgman K. i wsp. Achieving 24-Hour Control of Parkinson's Disease Symptoms: Use of Objective Measures to Improve Nocturnal Disability. Eur Neurol 2001; 46 (supl. 1): 3-10.
49. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
50. Tandberg E., Larsen J.P., Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998; 13: 895-899.
51. Chaudhuri K.R., Pal S., DiMarco A. i wsp. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 629-635.
52. Douglass A.B., Bornstein R., Nino-Murcia G. i wsp. The Sleep Disorders Questionnaire. I: Creation and multivariate structure of SDQ. Sleep 1994; 17: 160-167.
53. Fitzpatrick R., Peto V., Jenkinson C. i wsp. Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders. Mov Disord 1997; 12: 916-922.
54. Karlsen K.H., Larsen J.P., Tandberg E. i wsp. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66: 431-435.
55. Happe S., Berger K.; FAQT Study Investigators. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease - a prospective study. J Neurol 2001; 248: 1062-1067.
56. Happe S., Berger K. on behalf of the FATQ study investigators. The influence of poor sleep on quality of life in patients with parkinson's disease - a prospective study. Somnologie 2003; 7: 134-139.
57. Hauser R.A., Lyons K.E., Pahwa R. i wsp. Parkinson's Disease, Questions and Answers, Fourth Edition. Merit Publishing International, Hampshire 2003; pp. 121-123.
58. Reuter I., Ellis C.M., Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999; 100: 163-167.
59. Chaudhuri K.R., Bhattacharya K.F, Agapito C. i wsp. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: A parallel study with controlled release levodopa. Eur J Neurol 1999; 6 (supl. 5): S11-S15.
60. Arnulf I., Bejani B.P., Garma L. i wsp. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000; 55: 1732-1734.
61. Tan A., Salgado M., Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord 1996; 11: 214-216.
62. Hauser R.A., Wahba M.N., Zesiewicz T.A. i wsp. Modafinil treatment of pramipexole associated somnolence. Mov Disord 2000; 15: 1269-1271.